PMID- 8402683
OWN - NLM
STAT- MEDLINE
DCOM- 19931109
LR  - 20071114
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 53
IP  - 20
DP  - 1993 Oct 15
TI  - Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in 
      SCID/hu mice.
PG  - 4933-7
AB  - Mice with severe combined immunodeficiency (scid) provide an excellent model for 
      studying interactions between human tumor cells and effector cells of the immune 
      system. Because these animals lack functional B and T lymphocytes, they can 
      accept human tumor xenografts and transfer of human effector cells. Here, we 
      determined the ability of a human melanoma-specific, cytotoxic T-cell line (CTL) 
      in suppressing the growth of spontaneously metastasizing human melanoma cells M24 
      met (HLA-A11, A33) in scid mice. This CTL line was highly cytotoxic and 
      restricted by HLA-A11 against M24 met melanoma cells in vitro but poorly 
      cytotoxic when tested against a human melanoma cell line that did not express 
      HLA-A11. In order to evaluate the efficacy of this CTL line against M24 met 
      melanoma cells in vivo, randomized groups of animals were given injections of 
      either RPMI culture medium, interleukin 2 (IL-2), CTLs, or CTLs + IL-2. IL-2, per 
      se, did not significantly reduce tumor metastases; however, injection of 
      melanoma-specific, HLA-A11 restricted CTLs into scid mice, 1 day postexcision of 
      the previously induced primary tumor, markedly reduced the number of metastatic 
      foci in the lung and decreased metastatic involvement in lymph nodes. The 
      combination of these CTLs with IL-2 proved even more effective, since almost all 
      lung metastases were eradicated and metastatic involvement in both axillary and 
      inguinal lymph nodes was substantially reduced. Our results indicate that these 
      human CTLs maintain their ability for specific killing of metastasizing melanoma 
      cells in scid mice. Our data suggest that reconstitution of scid mice with a 
      specific group of effector cells (step-wise scid/hu) may be helpful for in vivo 
      evaluation of potentially useful cancer immunotherapy modalities.
FAU - Sabzevari, H
AU  - Sabzevari H
AD  - Department of Immunology, Scripps Research Institute, La Jolla, California 92037.
FAU - Reisfeld, R A
AU  - Reisfeld RA
LA  - eng
GR  - CA42508/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
SB  - IM
MH  - Animals
MH  - *Cytotoxicity, Immunologic
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - *Immunotherapy, Adoptive
MH  - Lung Neoplasms/pathology/*secondary/therapy
MH  - Melanoma/immunology/pathology/*secondary/*therapy
MH  - Mice
MH  - Mice, SCID
MH  - Neoplasm Metastasis
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Transplantation, Heterologous
EDAT- 1993/10/15 00:00
MHDA- 1993/10/15 00:01
CRDT- 1993/10/15 00:00
PHST- 1993/10/15 00:00 [pubmed]
PHST- 1993/10/15 00:01 [medline]
PHST- 1993/10/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1993 Oct 15;53(20):4933-7.